Watch CTXR. Know when insiders buy.
One email the day a filing lands. Free.
CTXR
Citius Pharmaceuticals, Inc.
0.58
+0.00 +0.52%
USD · close Sep 10
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
40
WATCH · shorts 40
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $16.1MP/E —DIV YIELD —FCF YIELD —REV TTM —NET INCOME −$58.2MNET CASH —52W 0.48 – 1.82SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q3 2026 · Jun 30 | $1.5M | — | 67.1% | −$11.7M | −$11.9M | — | -0.34 | −$8.7M | — | — | Aug 14 |
| Q2 2026 · Mar 31 | $1.7M | — | 80.3% | −$32.2M | −$28.1M | — | -0.95 | −$1.3M | — | — | Aug 14 |
| Q1 2026 · Dec 31 | $3.9M | — | 80.0% | −$9M | −$9.4M | — | -0.38 | −$13M | — | — | Aug 14 |
| Q4 2025 · Sep 30derived | — | — | — | −$8.4M | −$8.7M | — | -0.11 | −$11.9M | — | — | Dec 23 |
| Q3 2025 · Jun 30 | — | — | — | −$8.8M | −$9.2M | — | -0.80 | −$5.4M | — | — | Aug 14 |
| Q2 2025 · Mar 31 | — | — | — | −$11.3M | −$11.5M | — | -1.27 | −$4.5M | — | — | May 15 |
| Q1 2025 · Dec 31 | — | — | — | −$10M | −$10.3M | −211.4% | -1.30 | −$4.7M | — | — | Feb 13 |
| Q4 2024 · Sep 30derived | — | — | — | −$11.1M | −$11.1M | — | -1.60 | −$5.9M | — | — | Dec 23 |
| Q3 2024 · Jun 30 | — | — | — | −$10.6M | −$10.6M | — | -1.57 | −$8.4M | — | — | Aug 12 |
| Q2 2024 · Mar 31 | — | — | — | −$11M | −$8.5M | — | -1.34 | −$7.8M | — | — | May 14 |
| Q1 2024 · Dec 31 | — | — | — | −$9.3M | $9.2M | — | -1.45 | −$6.1M | — | — | May 14 |
| Q4 2023 · Sep 30derived | — | — | — | −$10.1M | −$9.9M | — | -5.42 | −$6.8M | — | — | Dec 27 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Sep 30 | — | — | −$38.5M | −$39.7M | — | -3.38 | −$26.6M | — | — | — | — |
| FY2024 · to Sep 30 | — | — | −$42M | −$39.4M | — | -5.97 | −$28.2M | — | — | — | — |
| FY2023 · to Sep 30 | — | — | −$36.7M | −$32.5M | — | -5.57 | −$29.1M | — | — | — | — |
| FY2022 · to Sep 30 | — | — | −$33.3M | −$33.6M | — | -0.23 | −$28.4M | — | — | — | — |
| FY2021 · to Sep 30 | — | — | −$23.5M | −$23.1M | — | -0.23 | −$24.3M | $7K | −$24.3M | — | — |
| FY2020 · to Sep 30 | — | — | −$17.7M | −$17.5M | — | -0.45 | −$16.9M | $2K | −$16.9M | — | — |
Every number comes from Citius Pharmaceuticals, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.